A detailed history of Jmac Enterprises LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Jmac Enterprises LLC holds 7,379 shares of BMY stock, worth $433,442. This represents 0.06% of its overall portfolio holdings.

Number of Shares
7,379
Previous 9,596 23.1%
Holding current value
$433,442
Previous $398,000 4.27%
% of portfolio
0.06%
Previous 0.07%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

SELL
$39.66 - $51.75 $87,926 - $114,729
-2,217 Reduced 23.1%
7,379 $381,000
Q2 2024

Jul 30, 2024

SELL
$40.25 - $52.99 $42,624 - $56,116
-1,059 Reduced 9.94%
9,596 $398,000
Q1 2024

Apr 30, 2024

BUY
$47.98 - $54.4 $5,805 - $6,582
121 Added 1.15%
10,655 $577,000
Q4 2023

Jan 26, 2024

SELL
$48.48 - $57.85 $79,361 - $94,700
-1,637 Reduced 13.45%
10,534 $540,000
Q3 2023

Oct 19, 2023

BUY
$57.89 - $64.73 $72,073 - $80,588
1,245 Added 11.39%
12,171 $706,000
Q2 2023

Jul 20, 2023

BUY
$63.71 - $70.74 $81,612 - $90,617
1,281 Added 13.28%
10,926 $698,000
Q1 2023

Apr 20, 2023

BUY
$65.71 - $74.53 $57,299 - $64,990
872 Added 9.94%
9,645 $668,000
Q4 2022

Jan 23, 2023

SELL
$68.48 - $81.09 $48,894 - $57,898
-714 Reduced 7.53%
8,773 $0
Q3 2022

Oct 20, 2022

BUY
$0.13 - $76.84 $15 - $9,297
121 Added 1.29%
9,487 $674,000
Q2 2022

Jul 25, 2022

SELL
$72.62 - $79.98 $16,194 - $17,835
-223 Reduced 2.33%
9,366 $721,000
Q1 2022

May 16, 2022

SELL
$61.48 - $73.72 $420,215 - $503,876
-6,835 Reduced 41.62%
9,589 $700,000
Q4 2021

Feb 14, 2022

BUY
$53.63 - $62.52 $880,819 - $1.03 Million
16,424 New
16,424 $1.08 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Jmac Enterprises LLC Portfolio

Follow Jmac Enterprises LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jmac Enterprises LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jmac Enterprises LLC with notifications on news.